Why Kratom Is Under Attack | Follow the Money
Investigation

Follow the Money

Why Kratom Is Really Under Attack: $258 Billion Reasons to Eliminate Natural Alternatives

The Numbers Tell the Story

When you're defending a quarter-trillion-dollar market, spending millions to eliminate a threat is just good business.

$258B
U.S. pharmaceutical markets threatened by kratom annually
$54-150K
Lost revenue per person who uses kratom instead of Suboxone (5-year treatment)
$75-150M
Annual spending on anti-kratom lobbying, PR campaigns, and astroturfing
48%
FDA budget from pharmaceutical industry fees—creating obvious conflicts of interest

The Players: Who's Behind the Attack

Big Pharma

What's at stake: $258B in threatened U.S. markets

  • Opioid pain medications: $24B/year
  • Mental health drugs: $67B/year
  • Addiction treatment (Suboxone): $42B/year
  • ADHD/energy medications: $38B/year

The strategy: Ban natural kratom, develop patented synthetics, charge 10-20x more

FDA & Revolving Door

The conflict: Regulate industry → Join industry → Profit

  • 48% of FDA budget from pharma fees
  • Scott Gottlieb: FDA → Pfizer board (2 months later)
  • Career incentives align with industry, not public
  • Post-FDA earnings: $2-3M annually from pharma

Addiction Treatment Industry

What's threatened: $42B addiction treatment market

  • MAT programs: $10K-30K per patient/year
  • Residential treatment: $20K-120K per stay
  • Suboxone: Lifetime dependency = $300K+ revenue
  • Kratom alternative: $1,500-3,000 total (5 years)

State Governments

The perverse incentive: Profit from expensive prescriptions

  • Medicaid rebates: $40-60B annually from pharma
  • Opioid settlement funds: $26B (requires treatment spending)
  • Federal matching funds for expensive care
  • Cheap alternatives = lost revenue streams

Pharma-Funded Legislators

The pattern: Take pharma money → Vote against kratom

  • Campaign contributions tied to anti-kratom votes
  • Model legislation copy-pasted across states
  • Same bill language appearing nationwide
  • Public records expose the money trail

Insurance & PBMs

The scam: Profit from complexity and high prices

  • PBMs earn $60-80B from rebate schemes
  • Higher drug prices = higher rebate payments
  • Kratom bypasses entire insurance system
  • Direct access threatens profitable gatekeeping

The Playbook: How They Do It

Tactic 1

Manipulate Death Statistics

Count any death where kratom was present—even with fentanyl, cocaine, or other drugs—as a "kratom death." Ignore that fentanyl alone explains most deaths. Result: Inflated statistics that terrify the public.

Tactic 2

Weaponize Contamination

When products are contaminated with salmonella or adulterants, blame kratom itself instead of pushing for quality standards. Use contamination as "proof" kratom is dangerous—while blocking the regulation that would prevent contamination.

Tactic 3

Fund Fake Grassroots Campaigns

Pay influencers $5K-50K to post scripted "kratom horror stories." Coordinate timing across 20-30 accounts. Create illusion of organic concern. Hide pharmaceutical funding through PR firm intermediaries.

Tactic 4

The Patent Trap

You can't patent a plant. Solution: Ban natural kratom, develop synthetic versions, patent them, charge $300-500/month instead of $30-50. Maintain monopoly pricing for 20 years. Already in motion—pharma companies have filed kratom alkaloid patents.

Tactic 5

State-Level Bans via Model Legislation

Create template bills. Send to pharma-funded legislators in multiple states. Same language appears nationwide. Looks like independent concern—actually coordinated strategy. Track campaign donations to see who's bought.

Tactic 6

Deploy the Nocebo Effect

Flood media with addiction horror stories. Create negative expectation. Users experience anxiety-induced symptoms, blame kratom. Victims become propagandists, validating the narrative. Self-reinforcing fear cycle.

The Double Standard

If this was really about safety, they'd be banning the wrong things. Here's what's ACTUALLY killing Americans—all while remaining completely legal.

Substance Annual U.S. Deaths Legal Status Why?
Kratom (pure) ~0-10 Threatened with Schedule I Threatens pharma profits
Alcohol ~95,000 Completely legal $250B industry + tax revenue
Tobacco ~480,000 Legal everywhere Tax revenue + settlement funds
Prescription Opioids ~17,000 Legal, FDA-approved Pharmaceutical profits
Tylenol ~500 Over-the-counter Pharmaceutical profits
NSAIDs (Ibuprofen) ~16,500 Over-the-counter Pharmaceutical profits

The pattern is clear: It's not about safety. It's about who profits.

Your State: Follow the Local Money

Six states have banned kratom. Track the pattern: pharma lobbying spending, campaign contributions to legislators, and identical bill language appearing across state lines.

Alabama
Arkansas
Indiana
Rhode Island
Vermont
Wisconsin

Want to know if YOUR representative took pharma money and voted against kratom? Search OpenSecrets.org for their pharmaceutical industry contributions.

What's Really at Stake

This isn't just about one plant. It's about who controls healthcare in America.

The current system: Gatekeepers (doctors, insurance companies, pharmaceutical corporations) control access to care and profit from complexity. Expensive prescriptions require doctor visits, insurance approval, pharmacy dispensing, ongoing monitoring. Every step generates revenue for someone.

The kratom model: Direct access. Personal choice. Affordability. No middlemen. No prescriptions. No insurance billing. No pharmaceutical patents. People managing their own health effectively without entering "the system."

The threat: If people realize they can manage chronic pain, quit opioids, address anxiety, and improve their lives with an affordable botanical—without prescriptions, without insurance, without pharmaceutical dependence—the entire for-profit healthcare model is threatened.

It's not about safety. It's about maintaining the profitable sickness model over the threat of affordable wellness.

Dig Deeper: Verify Everything

Don't take our word for it. Every claim on this page is backed by public records, financial disclosures, and documented evidence. Here's where to start your own investigation: